Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Lymphoma 21Neutropenia 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Carcinoma, Non-Small-Cell Lung 8Multiple Myeloma 7Leukemia 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Urinary Bladder Neoplasms 4Testicular Neoplasms 4Sarcoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Central Nervous System Neoplasms 4Testicular Germ Cell Tumor 3Teratoma 3Rhabdomyosarcoma 3Chemotherapy-induced Neutropenia 3Carcinoma, Ovarian Epithelial 3Carcinoma, Embryonal 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × pegfilgrastim × Clear all
NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡